In summary, for the first time, our study reveals “DHODH-induced uridine metabolism disruption/p53/mitochondrial pathway of apoptosis” as a new pathway underlying the effect of celastrol on APL cells, which provides novel insights into the application of celastrol in APL therapy. The gene discussed is TP53; the disease is acute promyelocytic leukemia.